---
title: "Provectus Biopharmaceuticals verlängert automatisches Umwandlungsdatum für Vorzugsaktien bis 2028"
description: "Provectus Biopharmaceuticals Inc. has announced the extension of the automatic conversion date for its Series D and Series D-1 Convertible Preferred Stock into common stock from June 20, 2026, to Dece"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274556313.md"
published_at: "2026-02-02T20:31:03.000Z"
---

# Provectus Biopharmaceuticals verlängert automatisches Umwandlungsdatum für Vorzugsaktien bis 2028

> Provectus Biopharmaceuticals Inc. has announced the extension of the automatic conversion date for its Series D and Series D-1 Convertible Preferred Stock into common stock from June 20, 2026, to December 31, 2028. The changes were approved by the board and a special committee consisting solely of independent members.

Provectus Biopharmaceuticals Inc. hat angekündigt, dass der Stichtag für die automatische Umwandlung der Series D und Series D-1 Convertible Preferred Stock in Stammaktien vom 20. Juni 2026 auf den 31. Dezember 2028 verschoben wird. Die Änderungen wurden vom Vorstand sowie einem ausschließlich aus unabhängigen Mitgliedern bestehenden Sonderausschuss genehmigt. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-004730), on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [BVS.US - Bioventus](https://longbridge.com/en/quote/BVS.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [NAVBQ.US - NAVIDEA BIOPHARMACEUTICALS INC](https://longbridge.com/en/quote/NAVBQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Bio-Works Technologies AB Receives 11 MSEK Order from Returning Biopharma Customer | Bio-Works Technologies AB has secured an 11 million SEK order from a returning biopharma customer for chromatography pro | [Link](https://longbridge.com/en/news/276129486.md) |
| Liminatus Pharma Announces $4 Million Public Offering With Warrants | Liminatus Pharma Inc. has announced a public offering of 13,813,000 shares of common stock and warrants to purchase up t | [Link](https://longbridge.com/en/news/276131390.md) |
| Annexon Inc. Hosts KOL Event Showcasing Vonaprument for Geographic Atrophy | Annexon Inc. will host a KOL event in New York on March 18, 2026, at 2:00 PM ET, focusing on dry AMD with geographic atr | [Link](https://longbridge.com/en/news/276126324.md) |
| Astro SA - Raport kwartalny za III kwartał | Additional attachments can be found below:20260216_163253_0000001214_0000064087.pdfnewsfile.refinitiv.com/getnewsfile/v1 | [Link](https://longbridge.com/en/news/276066262.md) |
| Envestnet Asset Management Inc. Sells 10,744 Shares of Jazz Pharmaceuticals PLC $JAZZ | Envestnet Asset Management Inc. reduced its stake in Jazz Pharmaceuticals PLC by 9.5%, selling 10,744 shares during Q3.  | [Link](https://longbridge.com/en/news/276105665.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.